Micardis

Negara: Uni Eropa

Bahasa: Inggris

Sumber: EMA (European Medicines Agency)

Beli Sekarang

Selebaran informasi Selebaran informasi (PIL)
03-11-2022
Karakteristik produk Karakteristik produk (SPC)
03-11-2022

Bahan aktif:

Telmisartan

Tersedia dari:

Boehringer Ingelheim International GmbH

Kode ATC:

C09CA07

INN (Nama Internasional):

telmisartan

Kelompok Terapi:

Angiotensin II antagonists, plain

Area terapi:

Hypertension

Indikasi Terapi:

HypertensionTreatment of essential hypertension in adults.Cardiovascular preventionReduction of cardiovascular morbidity in patients with:manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or;type-2 diabetes mellitus with documented target-organ damage.

Ringkasan produk:

Revision: 27

Status otorisasi:

Authorised

Tanggal Otorisasi:

1998-12-16

Selebaran informasi

                                44
B. PACKAGE LEAFLET
45
PACKAGE LEAFLET: INFORMATION FOR THE USER
MICARDIS 20 MG TABLETS
telmisartan
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Micardis is and what it is used for
2.
What you need to know before you take Micardis
3.
How to take Micardis
4.
Possible side effects
5.
How to store Micardis
6.
Contents of the pack and other information
1.
WHAT MICARDIS IS AND WHAT IT IS USED FOR
Micardis belongs to a class of medicines known as angiotensin II
receptor antagonists. Angiotensin II
is a substance produced in your body which causes your blood vessels
to narrow, thus increasing your
blood pressure. Micardis blocks the effect of angiotensin II so that
the blood vessels relax, and your
blood pressure is lowered.
MICARDIS IS USED TO treat essential hypertension (high blood pressure)
in adults. ‘Essential’ means
that the high blood pressure is not caused by any other condition.
High blood pressure, if not treated, can damage blood vessels in
several organs, which could lead
sometimes to heart attack, heart or kidney failure, stroke, or
blindness. There are usually no symptoms
of high blood pressure before damage occurs. Thus it is important to
regularly measure blood pressure
to verify if it is within the normal range.
MICARDIS IS ALSO USED TO reduce cardiovascular events (i.e. heart
attack or stroke) in adults who are at
risk because they have a reduced or blocked blood supply to the heart
or legs, or have had a stroke or
have high risk diabetes. Your doctor can tell you if you are 
                                
                                Baca dokumen lengkapnya
                                
                            

Karakteristik produk

                                ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Micardis 20 mg tablets
Micardis 40 mg tablets
Micardis 80 mg tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Micardis 20 mg tablets
Each tablet contains 20 mg telmisartan.
Micardis 40 mg tablets
Each tablet contains 40 mg telmisartan.
Micardis 80 mg tablets
Each tablet contains 80 mg telmisartan.
Excipients with known effect
Each 20 mg tablet contains 84 mg sorbitol (E420).
Each 40 mg tablet contains 169 mg sorbitol (E420).
Each 80 mg tablet contains 338 mg sorbitol (E420).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablet
Micardis 20 mg tablets
White round tablets of 2.5 mm engraved with the code number '50H' on
one side and the company
logo on the other side.
Micardis 40 mg tablets
White oblong tablets of 3.8 mm engraved with the code number '51H' on
one side and the company
logo on the other side.
Micardis 80 mg tablets
White oblong tablets of 4.6 mm engraved with the code number '52H' on
one side and the company
logo on the other side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Hypertension
Treatment of essential hypertension in adults.
3
Cardiovascular prevention
Reduction of cardiovascular morbidity in adults with:

manifest atherothrombotic cardiovascular disease (history of coronary
heart disease, stroke, or
peripheral arterial disease) or

type 2 diabetes mellitus with documented target organ damage
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Treatment of essential hypertension_
The usually effective dose is 40 mg once daily. Some patients may
already benefit at a daily dose of
20 mg. In cases where the target blood pressure is not achieved, the
dose of telmisartan can be
increased to a maximum of 80 mg once daily. Alternatively, telmisartan
may be used in combination
with thiazide-type diuretics such as hydrochlorothiazide, which has
been shown to have an additive
blood pressure lowering effect with telmisartan. When considering
raising the dose, it must be borne
in mind
                                
                                Baca dokumen lengkapnya
                                
                            

Dokumen dalam bahasa lain

Selebaran informasi Selebaran informasi Bulgar 03-11-2022
Karakteristik produk Karakteristik produk Bulgar 03-11-2022
Laporan Penilaian publik Laporan Penilaian publik Bulgar 06-11-2015
Selebaran informasi Selebaran informasi Spanyol 03-11-2022
Karakteristik produk Karakteristik produk Spanyol 03-11-2022
Laporan Penilaian publik Laporan Penilaian publik Spanyol 06-11-2015
Selebaran informasi Selebaran informasi Cheska 03-11-2022
Karakteristik produk Karakteristik produk Cheska 03-11-2022
Laporan Penilaian publik Laporan Penilaian publik Cheska 06-11-2015
Selebaran informasi Selebaran informasi Dansk 03-11-2022
Karakteristik produk Karakteristik produk Dansk 03-11-2022
Laporan Penilaian publik Laporan Penilaian publik Dansk 06-11-2015
Selebaran informasi Selebaran informasi Jerman 03-11-2022
Karakteristik produk Karakteristik produk Jerman 03-11-2022
Laporan Penilaian publik Laporan Penilaian publik Jerman 06-11-2015
Selebaran informasi Selebaran informasi Esti 03-11-2022
Karakteristik produk Karakteristik produk Esti 03-11-2022
Laporan Penilaian publik Laporan Penilaian publik Esti 06-11-2015
Selebaran informasi Selebaran informasi Yunani 03-11-2022
Karakteristik produk Karakteristik produk Yunani 03-11-2022
Laporan Penilaian publik Laporan Penilaian publik Yunani 06-11-2015
Selebaran informasi Selebaran informasi Prancis 03-11-2022
Karakteristik produk Karakteristik produk Prancis 03-11-2022
Laporan Penilaian publik Laporan Penilaian publik Prancis 06-11-2015
Selebaran informasi Selebaran informasi Italia 03-11-2022
Karakteristik produk Karakteristik produk Italia 03-11-2022
Laporan Penilaian publik Laporan Penilaian publik Italia 06-11-2015
Selebaran informasi Selebaran informasi Latvi 03-11-2022
Karakteristik produk Karakteristik produk Latvi 03-11-2022
Laporan Penilaian publik Laporan Penilaian publik Latvi 06-11-2015
Selebaran informasi Selebaran informasi Lituavi 03-11-2022
Karakteristik produk Karakteristik produk Lituavi 03-11-2022
Laporan Penilaian publik Laporan Penilaian publik Lituavi 06-11-2015
Selebaran informasi Selebaran informasi Hungaria 03-11-2022
Karakteristik produk Karakteristik produk Hungaria 03-11-2022
Laporan Penilaian publik Laporan Penilaian publik Hungaria 06-11-2015
Selebaran informasi Selebaran informasi Malta 03-11-2022
Karakteristik produk Karakteristik produk Malta 03-11-2022
Laporan Penilaian publik Laporan Penilaian publik Malta 06-11-2015
Selebaran informasi Selebaran informasi Belanda 03-11-2022
Karakteristik produk Karakteristik produk Belanda 03-11-2022
Laporan Penilaian publik Laporan Penilaian publik Belanda 06-11-2015
Selebaran informasi Selebaran informasi Polski 03-11-2022
Karakteristik produk Karakteristik produk Polski 03-11-2022
Laporan Penilaian publik Laporan Penilaian publik Polski 06-11-2015
Selebaran informasi Selebaran informasi Portugis 03-11-2022
Karakteristik produk Karakteristik produk Portugis 03-11-2022
Laporan Penilaian publik Laporan Penilaian publik Portugis 06-11-2015
Selebaran informasi Selebaran informasi Rumania 03-11-2022
Karakteristik produk Karakteristik produk Rumania 03-11-2022
Laporan Penilaian publik Laporan Penilaian publik Rumania 06-11-2015
Selebaran informasi Selebaran informasi Slovak 03-11-2022
Karakteristik produk Karakteristik produk Slovak 03-11-2022
Laporan Penilaian publik Laporan Penilaian publik Slovak 06-11-2015
Selebaran informasi Selebaran informasi Sloven 03-11-2022
Karakteristik produk Karakteristik produk Sloven 03-11-2022
Laporan Penilaian publik Laporan Penilaian publik Sloven 06-11-2015
Selebaran informasi Selebaran informasi Suomi 03-11-2022
Karakteristik produk Karakteristik produk Suomi 03-11-2022
Laporan Penilaian publik Laporan Penilaian publik Suomi 06-11-2015
Selebaran informasi Selebaran informasi Swedia 03-11-2022
Karakteristik produk Karakteristik produk Swedia 03-11-2022
Laporan Penilaian publik Laporan Penilaian publik Swedia 06-11-2015
Selebaran informasi Selebaran informasi Norwegia 03-11-2022
Karakteristik produk Karakteristik produk Norwegia 03-11-2022
Selebaran informasi Selebaran informasi Islandia 03-11-2022
Karakteristik produk Karakteristik produk Islandia 03-11-2022
Selebaran informasi Selebaran informasi Kroasia 03-11-2022
Karakteristik produk Karakteristik produk Kroasia 03-11-2022
Laporan Penilaian publik Laporan Penilaian publik Kroasia 06-11-2015

Peringatan pencarian terkait dengan produk ini

Lihat riwayat dokumen